Yizhe Wang, LianBio CEO
Pfizer opts in to net LianBio’s rights to RSV candidate, putting down $20M upfront
Pfizer and LianBio have had a relationship for over two years now, but the pharma’s latest move will see it grab a candidate from LianBio …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
